Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62.7M
-
Number of holders
-
191
-
Total 13F shares, excl. options
-
53.5M
-
Shares change
-
-4.48M
-
Total reported value, excl. options
-
$581M
-
Value change
-
-$65.1M
-
Put/Call ratio
-
0.24
-
Number of buys
-
106
-
Number of sells
-
-89
-
Price
-
$10.86
Significant Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q2 2024
247 filings reported holding SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") as of Q2 2024.
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) has 191 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53.5M shares
of 62.7M outstanding shares and own 85.42% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (6.42M shares), FMR LLC (5.82M shares), RTW INVESTMENTS, LP (5.48M shares), BlackRock Inc. (5.22M shares), Bellevue Group AG (4.46M shares), STATE STREET CORP (2.47M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (1.43M shares), MORGAN STANLEY (1.39M shares), GEODE CAPITAL MANAGEMENT, LLC (1.24M shares), and JPMORGAN CHASE & CO (1.2M shares).
This table shows the top 191 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.